A human colorectal adenocarcinoma model used to investigate colon epithelial differentiation, Wnt signalling, and targeted therapies. Available exclusively from CancerTools. Save 30% on this cell line this autumn. Use code ACA26CELL at checkout.
| Inventor | Institute |
|---|---|
| Walter Bodmer | University of Oxford |
| SKU: | 152434 |
|---|---|
| Product description: | The SW1222 cell line was established from a patient with a moderately well differentiated adenocarcinoma of the colon classified as Dukes’ stage C. SW1222 cells produce tumours in female athymic nu/nu nude mice. |
| Conditional: | Yes |
| Additional notes: | STR-PCR Data: Amelogenin: X,Y CSF1PO: 11 D13S317: 9,13 D16S539: 9,10 D5S818: 9 D7S820: 10,12 THO1: 7 TPOX: 10 vWA: 18 |
| Cellosaurus ID: | CVCL_3886 |
| Disease: | Cancer |
| Cat. #: | 152434 |
|---|---|
| Provenance and Ownership: | The SW1222 Cell Line is owned by Cancer Research UK. CancerTools supplies the SW1222 Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing SW1222 Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Colorectal cancer |
| Research Fields: | Cancer;Drug development |
| Organism: | Human |
| Tissue: | Colon |
| Growth properties: | Growth mode: adherent |
| Cancer Types In Detail: | Human colorectal adenocarcinoma |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Iscove’s Modified Dulbecco’s Medium, + 10% Foetal Bovine Serum (FBS) + 2 mM Glutamine |
| Subculture routine: | Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4×10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. |
| References: |
Rinne et al. 2025. Theranostics. 15(15):7489-7500. PMID: 40756357. Shaala et al. 2025. Mar Drugs. 23(7):262. PMID: 40710487. Perez-Pedroza et al. 2024. J Vis Exp. PMID: 38767378. Vaughn et al. 2024. J Nucl Med. 65(10):1611-1618. PMID: 39168519. Delaney et al. 2023. Mol Imaging Biol. 25(6):1104-1114. PMID: 37052759. Abdelrahman et al. 2021. Molecules. 26(16):4730. PMID: 34443319. Bacac et al. 2016. Clin Cancer Res. 22(13):3286-3297. PMID: 26861458. Hsia et al. 2016. Proc Natl Acad Sci U S A. 113(15):E2162-2171.PMID: 27036009. Yeung et al. 2010. Proc Natl Acad Sci U S A. 107(8):3722-3727. PMID: 20133591. Efstathiou et al. 1999. Proc Natl Acad Sci U S A. 96(5):2316-2321. PMID: 10051639. Browning et al. 1993. J Immunother Emphasis Tumor Immunol. 14(3):163-168. PMID: 8297898. Richman et al. 1988. J Pathol. 156(3):197-211. PMID: 3204451. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.